Regeneron Pharmaceuticals Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
π Regeneron Pharmaceuticals Inc. (REGN) shares fell 6.21% to $686.36 on Wednesday, trailing competitors in performance.
π₯ The decline occurred during a broader market downturn as the S&P 500 dipped 0.04% and the Dow Jones Industrial Average dropped 0.57%.
π This marks Regeneron's fourth consecutive day of losses since April 29, 2026.
π MarketWatch provided real-time data powered by FactSet and Automated Insights for the article content.
β οΈ Intraday stock quotes reflect trades reported through Nasdaq only with a delay of at least 15 minutes.
Bullish Signals
- Regeneron Pharmaceuticals Inc. (REGN) continues to operate in a market supported by world-class data from Dow Jones and FactSet.
- The article notes Regeneron's stock trading within an environment that includes partnerships with Automated Insights for providing latest, pertinent content at record speed.
Risk Factors
- Regeneron's stock fell 6.21% to $686.36 on Wednesday, marking the fourth consecutive day of losses.
- The sharp decline occurred during a broader market downturn with the S&P 500 down 0.04% and the Dow Jones Industrial Average dropping 0.57%.
Full Analysis
Regeneron Pharmaceuticals Inc. (REGN) stock experienced a decline of 6.21% on Wednesday, closing at $686.36. This underperformance occurred during an overall weak trading session for the broader market, with the S&P 500 Index SPX falling 0.04% to 7,135.95 and the Dow Jones Industrial Average DJIA dropping 0.57% to 48,861.81. Notably, this marked the fourth consecutive day that Regeneron shares have posted losses, indicating a sustained period of negative momentum for the biotechnology company's equity.
MarketWatch reported the movement on April 29, 2026, at 4:30 p.m. ET, providing real-time and delayed stock data subject to Nasdaq exchange requirements and intraday delays of at least 15 minutes where applicable. The article contextualizes Regeneron's performance within the general market downturn but does not specify a competitor for direct comparison beyond the headline noting it underperformed relative to peers on Wednesday.
The financial data provided by MarketWatch, supported by Dow Jones and FactSet, reflects standard reporting practices with all quotes in local exchange time and real-time last sale data covering U.S. stock trades reported through Nasdaq only. The copyright notice indicates the content is owned by MarketWatch, Inc., as of 2026.